Top Investors’ Stock Portfolio: 5 Mid-Cap Stocks To Buy

2. Mirati Therapeutics, Inc. (NASDAQ:MRTX

Number of Hedge Fund Holders: 55
Market Cap: $8.9 billion 

Mirati Therapeutics, Inc. (NASDAQ:MRTX) is a clinical-stage biotech company that discovers and delivers breakthrough therapies to treat patients with serious conditions, such as cancer. The company stands second on our list of the top mid-cap stocks to buy. 

Recently, Mirati Therapeutics, Inc. (NASDAQ:MRTX) reported a positive result from its phase two study of evaluating adagrasib in patients with advanced lung cancer. The company plans to submit the detailed result in early 2022. In September, Stifel initiated its coverage on Mirati Therapeutics, Inc. (NASDAQ:MRTX) with a ‘Buy’ rating and a $202 price target, highlighting the company’s successful recent adagrasib data. At the end of Q2 2021, Mirati Therapeutics, Inc. (NASDAQ:MRTX) reported cash and cash equivalents of $1.2 billion. 

Of the 873 hedge funds tracked by Insider Monkey, 55 hedge funds have positions in Mirati Therapeutics, Inc. (NASDAQ:MRTX) in Q2 2021, compared with 57 in the previous quarter. The total value of these stakes is $2.79 billion.